These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 38604544

  • 1. Novel combinatorial autophagy inhibition therapy for triple negative breast cancers.
    Abd El-Aziz YS, Toit-Thompson TD, McKay MJ, Molloy MP, Stoner S, McDowell B, Moon E, Sioson L, Sheen A, Chou A, Gill AJ, Jansson PJ, Sahni S.
    Eur J Pharmacol; 2024 Jun 15; 973():176568. PubMed ID: 38604544
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
    Cocco S, Leone A, Roca MS, Lombardi R, Piezzo M, Caputo R, Ciardiello C, Costantini S, Bruzzese F, Sisalli MJ, Budillon A, De Laurentiis M.
    J Transl Med; 2022 Jun 27; 20(1):290. PubMed ID: 35761360
    [Abstract] [Full Text] [Related]

  • 3. Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3.
    Ünal TD, Hamurcu Z, Delibaşı N, Çınar V, Güler A, Gökçe S, Nurdinov N, Ozpolat B.
    Anticancer Agents Med Chem; 2021 Jun 27; 21(3):355-364. PubMed ID: 32767958
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS, Chang JC.
    Breast Cancer Res; 2015 Feb 22; 17(1):25. PubMed ID: 25849745
    [Abstract] [Full Text] [Related]

  • 5. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.
    Bousquet G, El Bouchtaoui M, Sophie T, Leboeuf C, de Bazelaire C, Ratajczak P, Giacchetti S, de Roquancourt A, Bertheau P, Verneuil L, Feugeas JP, Espié M, Janin A.
    Oncotarget; 2017 May 23; 8(21):35205-35221. PubMed ID: 28445132
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of autophagy initiation: A novel strategy for oral squamous cell carcinomas.
    Abd El-Aziz YS, McKay MJ, Molloy MP, McDowell B, Moon E, Sioson L, Sheen A, Chou A, Gill AJ, Jansson PJ, Sahni S.
    Biochim Biophys Acta Mol Cell Res; 2024 Feb 23; 1871(2):119627. PubMed ID: 37963518
    [Abstract] [Full Text] [Related]

  • 7. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
    Zhen Y, Zhao R, Wang M, Jiang X, Gao F, Fu L, Zhang L, Zhou XL.
    Theranostics; 2020 Feb 23; 10(18):8080-8097. PubMed ID: 32724459
    [Abstract] [Full Text] [Related]

  • 8. Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release.
    Ma Y, Xie D, Chen Z, Shen X, Wu X, Ding F, Ding S, Pan Y, Li F, Lu A, Zhang G.
    J Transl Med; 2024 Jul 01; 22(1):604. PubMed ID: 38951906
    [Abstract] [Full Text] [Related]

  • 9. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
    Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeysundara N, Leung A, Go NE, DeVorkin L, Weppler SA, Gelmon K, Yapp DT, Bally MB, Gorski SM.
    Clin Cancer Res; 2014 Jun 15; 20(12):3159-73. PubMed ID: 24721646
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
    Shetti D, Zhang B, Fan C, Mo C, Lee BH, Wei K.
    Cells; 2019 Aug 14; 8(8):. PubMed ID: 31416135
    [Abstract] [Full Text] [Related]

  • 13. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS, Ho Y, Lin YW, Naveen Raj E, Liu KK, Chen C, Zhou XZ, Lu KP, Chao JI.
    Acta Biomater; 2019 Mar 01; 86():395-405. PubMed ID: 30660004
    [Abstract] [Full Text] [Related]

  • 14. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
    Thies KA, Cole MW, Schafer RE, Spehar JM, Richardson DS, Steck SA, Das M, Lian AW, Ray A, Shakya R, Knoblaugh SE, Timmers CD, Ostrowski MC, Chakravarti A, Sizemore GM, Sizemore ST.
    Breast Cancer Res; 2021 Jun 12; 23(1):65. PubMed ID: 34118960
    [Abstract] [Full Text] [Related]

  • 15. IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells.
    Wu M, Zhang L, Pi L, Liu L, Wang S, Wu Y, Pan H, Liu M, Yi Z.
    Cell Oncol (Dordr); 2024 Oct 12; 47(5):1797-1809. PubMed ID: 38888849
    [Abstract] [Full Text] [Related]

  • 16. ADT-OH exhibits anti-metastatic activity on triple-negative breast cancer by combinatorial targeting of autophagy and mitochondrial fission.
    Yu S, Cao Z, Cai F, Yao Y, Chang X, Wang X, Zhuang H, Hua ZC.
    Cell Death Dis; 2024 Jun 28; 15(6):463. PubMed ID: 38942765
    [Abstract] [Full Text] [Related]

  • 17. Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.
    Sato K, Padgaonkar AA, Baker SJ, Cosenza SC, Rechkoblit O, Subbaiah DRCV, Domingo-Domenech J, Bartkowski A, Port ER, Aggarwal AK, Ramana Reddy MV, Irie HY, Reddy EP.
    Nat Commun; 2021 Aug 03; 12(1):4671. PubMed ID: 34344863
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.